ArticleBreast cancer (Dove Medical Press)2025
LINC00917 Promotes Bone Metastasis of Breast Cancer by Targeting the miR-491-5p/FOXP4 Axis.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Breast cancer is one of the most common malignant tumors in women. Advanced patients often experience distant metastasis, among which bone metastasis has a relatively high incidence rate, seriously affecting the quality of life and prognosis of patients. LINC00917 may be related to the prognosis of breast cancer patients. This study aims to explore whether LINC00917 plays a significant role in breast cancer bone metastasis by targeting and regulating the expression of miR-491-5p. Patients and methods: 254 breast cancer patients were recruited. The levels of LINC00917 were examined by RT-qPCR. Furthermore, the association between LINC00917 expression and patient prognosis was evaluated using Kaplan-Meier curves and Cox regression analysis. An in vitro cell model was established, and CCK-8 and Transwell assays were conducted to explore the role of LINC00917 in breast cancer bone metastasis. Additionally, the interaction among LINC00917, miR-491-5p, and FOXP4 were examined using dual-luciferase reporter assays. Results: LINC00917 was upregulated in breast cancer bone metastasis and was associated with bad prognosis. Additionally, the knockdown of LINC00917 inhibited the function of breast cancer cells, and suppressed osteoclastogenesis while promoting osteoblast differentiation. Moreover, miR-491-5p inhibition counteracted the effects of LINC00917 knockdown on cell models. Furthermore, FOXP4 may be a target gene of miR-491-5p. Conclusion: LINC00917 is a potential prognostic indicator for breast cancer bone metastasis. It is proposed that LINC00917 may facilitate the bone metastasis process in breast cancer by modulating the miR-491-5p/FOXP4 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.